Improvement of non-alcoholic fatty liver disease treatment

Abstract

Aim of investigation. To estimate efficacy of combined hepatotropic drug «Hepaguard Active» for prevention of progression of non-alcoholic fatty liver disease (NAFLD) at steatosis stage.Material and methods. Overall 25 patients with verified NAFLD at steatosis stage were studied. All patients received Hepaguard Active 1 capsule tid at meal time for 3 months. Before and after treatment course general examination was performed, including: inquiry and physical examination, clinical and biochemical blood tests, FibroMax tests, large intestine contents culture, bioimpedance analysis of componental body composition, ultrasound investigation of abdominal organs.Results. On a background of «Hepaguard Active» therapy improvement of symptoms was marked, condition of hepatobiliary tract has improved, lipid spectrum was normalized, excessive body weight decreased, quality of life improved.Conclusions. Hepaguard Active can be recommended to patients with NAFLD at steatosis stage for correction of revealed disorders and prevention of disease progression.

Keywords

• non-alcoholic fatty liver disease
• steatosis
• hepaguard active